| Samantha Nicole Granville, LVN | |
|
87-136 Kulala Pl, Waianae, HI 96792-3364 | |
| (760) 646-6006 | |
| Not Available |
| Full Name | Samantha Nicole Granville |
|---|---|
| Gender | Female |
| Speciality | Licensed Vocational Nurse |
| Location | 87-136 Kulala Pl, Waianae, Hawaii |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1265839229 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 164X00000X | Licensed Vocational Nurse | 252862 (California) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Samantha Nicole Granville, LVN 87-136 Kulala Pl, Waianae, HI 96792-3364 Ph: (760) 646-6006 | Samantha Nicole Granville, LVN 87-136 Kulala Pl, Waianae, HI 96792-3364 Ph: (760) 646-6006 |
News Archive
The European Commission has approved a personalized cellular therapy developed at the University of Pennsylvania's Abramson Cancer Center, making it the first chimeric antigen receptor (CAR) T cell therapy permitted for use in the European Union in two distinct indications.
Bioniche Pharma, a leading developer and manufacturer of injectable pharmaceuticals, and Synerx Pharma, LLC announced today the FDA approval and launch of Isosulfan Blue Injection 1%.
In an article published ahead of print on November 24, 2015 in the journal Diabetes (available at http://dx.doi.org/10.2337/db15-0930), researchers from the Medical University of South Carolina, the American University of Beirut, and Case Western Reserve University report that a molecule called pre-kallikrein (PK) could be a target for the vascular complications associated with type 1 diabetes.
Eleven Biotherapeutics (NASDAQ: EBIO), a clinical-stage biopharmaceutical company discovering and developing protein therapeutics to treat diseases of the eye, today announced that patient randomization and dosing are underway in the Company's first pivotal Phase 3 clinical study of EBI-005 for the treatment of moderate to severe dry eye disease (DED), the OASIS study (A Multi-Center, Double-Masked, Randomized, Controlled, Efficacy and Safety Study of EBI-005 5 mg/mL Topical Ophthalmic Solution Versus Vehicle Control In Subjects With Moderate to Severe Dry Eye Disease).
Assurance of a cancer-free status did not prompt people participating in a long-term computerized tomography (CT) lung-cancer screening program to pick up their cigarettes again, researchers wrote in a study published in Cancer Epidemiology, Biomarkers & Prevention, a journal of the American Association for Cancer Research.
› Verified 5 days ago